GGrantIndex
Sort

261,768 grants matching gene therapy

Cardiac lineage determination and nuclear architecture

$957,952
Jonathan A Epstein · University Of Pennsylvania · R35 · FY2019 · HL

Cardiac lineage determination and nuclear architecture

$957,952
Jonathan A Epstein · University Of Pennsylvania · R35 · FY2020 · HL

Cardiac lineage determination and nuclear architecture

$957,952
Jonathan A Epstein · University Of Pennsylvania · R35 · FY2023 · HL

2-HOBA for Treatment of Pulmonary Hypertension

$957,913
John A Rathmacher · Mti Biotech, Inc. · R42 · FY2025 · HL

2-HOBA for Treatment of Pulmonary Hypertension

$957,913
John A Rathmacher · Mti Biotech, Inc. · R42 · FY2024 · HL

Transgenic T cell Therapy for Acute Myeloid Leukemia

$957,908
Aude Chapuis · Fred Hutchinson Cancer Center · P01 · FY2025 · CA

Transgenic T cell Therapy for Acute Myeloid Leukemia

$957,908
Aude Chapuis · Fred Hutchinson Cancer Center · P01 · FY2024 · CA

Role of inflammation, innate resistance, and immunity in carcinogenesis

$957,864
Giorgio Trinchieri · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA

Commercialization of PANDAA qDx for rapid drug resistance genotyping of protease inhibitor ART failures in resource-limited settings.

$957,844
Iain James Macleod · Aldatu Biosciences, Inc. · SB1 · FY2024 · AI

Red Cell Biology

$957,817
David M. Bodine · National Human Genome Research Institute · ZIA · FY2018 · HG

Effects of Time-restricted Eating versus Daily Continuous Calorie Restriction on Body Weight and Colorectal Cancer Risk Markers among Adults with Obesity

$957,734
Lisa Tussing-Humphreys · University Of Illinois At Chicago · R01 · FY2025 · CA

Kinase Targeted Antimalarial Agents

$957,654
Reena Zutshi · Luceome Biotechnologies, Llc · R44 · FY2020 · AI

Molecular Mechanisms Of The Autoimmune Lymphoproliferative Syndrome

$957,638
Michael J Lenardo · National Institute Of Allergy And Infectious Diseases · ZIA · FY2016 · AI

A Randomized Phase 2A Clinical Trial Pioneering the Utility of an eNAMPT-Reducing Therapy in ARDS/VILI: the PUERTA Trial

$957,594
Joe G. N. Garcia · Aqualung Therapeutics Corp. · R44 · FY2024 · HL

DNA Repair, Cell Cycle Checkpoints and Apoptosis as Targets for Anticancer Drugs

$957,460
Yves Pommier · Division Of Basic Sciences - Nci · ZIA · FY2013 · CA

Determining the Fate of Transmembrane Proteins

$957,415
Allan M Weissman · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA

Targeted therapies for Kaposi sarcoma and KSHV-multicentric Castleman disease

$957,389
Ramya Ramaswami · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA

CENTER FOR CEREBROVASCULAR DISEASE

$957,351
Stanford University · P01 · FY2003 · NS

Predicting Cancer Cell Response to Endogenous and Exogenous Perturbations at the Single Cell Level

$957,321
Andrea Califano · Columbia University Health Sciences · R35 · FY2023 · CA

An integrated genotyping approach for HLA and other genetic systems

$957,318
Wyatt Nelson · Scisio Genetics, Inc. · R44 · FY2015 · AI

Longitudinal Cognitive ERP studies: Advancement for AD Clinical Trials

$957,278
John M Olichney · University Of California At Davis · R01 · FY2016 · AG

Refanalin for lung preservation and transplantation

$957,162
Weizhong Cai · Angion Biomedica Corporation · R44 · FY2008 · HL

Emerging therapeutic candidates for rare maternally inherited mitochondrial diseases with shared etiologies

$957,084
Anne E Chiaramello · George Washington University · UH3 · FY2023 · TR

Metabolic Networks and Pathways in Alzheimer's Disease

$957,041
Rima F Kaddurah-Daouk · Duke University · R01 · FY2015 · AG

Cell and Cancer Biology Branch Confocal Microscopy Core

$957,040
Yvona Ward · Division Of Basic Sciences - Nci · ZIC · FY2011 · CA